As PRMT5 is inhibited by the accumulation of the unprocessed MTAP metabolite MTA in tumor cells [11], MTAP deficiency makes these cells more susceptible to PRMT5- or MAT2A-inhibiting drugs (summarized in [7]). This evidence concerns the gene MAT2A and neoplasm.